Sensei Biotherapeutics (NASDAQ:FTH) Issues Earnings Results

Sensei Biotherapeutics (NASDAQ:FTH) released its quarterly earnings results on Tuesday. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($5.04) by $4.42, FiscalAI reports.

Sensei Biotherapeutics Price Performance

Sensei Biotherapeutics stock opened at $25.06 on Tuesday. Sensei Biotherapeutics has a 52 week low of $7.20 and a 52 week high of $37.90. The stock has a market cap of $33.63 million, a P/E ratio of -0.17 and a beta of -0.26.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on FTH shares. Robert W. Baird assumed coverage on shares of Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 price target on the stock. Raymond James Financial initiated coverage on Sensei Biotherapeutics in a report on Friday. They issued an “outperform” rating and a $56.00 price target for the company. Citizens Jmp began coverage on shares of Sensei Biotherapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price objective for the company. Leerink Partners assumed coverage on shares of Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 target price for the company. Finally, Weiss Ratings began coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Sensei Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $54.89.

Insider Buying and Selling

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the transaction, the insider directly owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. This trade represents a 16.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Anand Kiran Parikh acquired 2,806 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were acquired at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the purchase, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have acquired 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) by 10.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the period. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.